Namely, the vascular endothelial growth factor receptor (VEGFR), the fibroblast growth factor receptor (FGFR), the platelet-derived growth factor receptor (PDGFR), the AXL/UFO receptor tyrosine kinase, the insulin-like growth factor 1 receptor (IGF1R), and still other RTKs similarly appear to contribute to the observed resistance to EGFR inhibition in NSCLC [105-109]. The gene discussed is AXL; the disease is non-small cell lung carcinoma.